Results 221 to 230 of about 73,275 (286)

TLR9 Inhibition Shortly After Mating Increases Fetal Resorption and Alters B- and T-Cell Costimulatory Phenotypes in an Abortion-Prone Mouse Model. [PDF]

Int J Mol Sci
Lorek D, Kedzierska AE, Slawek A, Kubik P, Chelmonska-Soyta A.   +4 more
europepmc   +1 more source

Aging‐Derived Alterations in Genomic, Immune, and Metabolic Networks: Implications for Cancer Development and Therapy

MedComm – Oncology, Volume 5, Issue 1, March 2026.
Ageing acts as a double‐edged sword in cancer. In the elderly, open chromatin, immunosenescence, and chronic inflammation drive SASP (IL‐6, MMPs), MDSC accumulation and T‐cell suppression, fostering tumor‐promoting microenvironments and limited therapeutic benefit.
Qi Wang, Xue Sun, Xinhao Han, Xingda Zhang, Wenzheng Wang, Hongbin Wang, He Ren, Lina Gu   +7 more
wiley   +1 more source

Characterization of the SARS-CoV-2-Specific T Cell Responses in Rheumatoid Arthritis Subjects Vaccinated for COVID-19 Protection. [PDF]

Eur J Immunol
Song J, da Silva Antunes R, Seyede MA, Guma M, Sette A, Franco A.   +5 more
europepmc   +1 more source

The impact of Foxp3+ regulatory T‐cells on CD8+ T‐cell dysfunction in tumour microenvironments and responses to immune checkpoint inhibitors

British Journal of Pharmacology, Volume 183, Issue 6, Page 1250-1270, March 2026.
Immune checkpoint inhibitors (ICIs) have been a breakthrough in cancer therapy, inducing durable remissions in responding patients. However, they are associated with variable outcomes, spanning from disease hyperprogression to complete responses with the onset of immune‐related adverse events.
Mikhaël Attias, Ciriaco A. Piccirillo
wiley   +1 more source

CD4/CD8-p56^lck Induced T-Cell Receptor Signaling and Its Implications for Immunotherapy. [PDF]

Biomolecules
Oroya A, Rudd CE.
europepmc   +1 more source

Transplant vascular sclerosis: from pathogenesis to prevention [PDF]

Aitouche, A, Fung, JJ, Rao, AS, Starzl, TE, Subbotin, V, Sun, H, Tang, JL, Valdivia, LA   +7 more
core  

Dendritic cells and the balance between transplant tolerance and immunity [PDF]

, 1996
Lu, L, Starzl, TE, Steptoe, RJ, Thomson, AW   +3 more
core  

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, Volume 183, Issue 6, Page 1271-1287, March 2026.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

MDX-2001-101 study protocol: a phase I/IIa, multicenter, first-in-human, open-label clinical trial evaluating MDX2001 monotherapy in patients with advanced solid tumors. [PDF]

Future Oncol
Dumbrava E, Minchom A, Henry J, Johnson M, Sommerhalder D, Merchan J, Heist R, Cabanas EG, Cotreau M, Goenaga AL, Burzyn D, Makris L, Culm K, Abbadessa G.   +13 more
europepmc   +1 more source

Tui Na Acupressure Modulates Treg Immunosuppression via FoxP3/mTORC1 Signalling in ALS Mice

Immunology, Volume 177, Issue 3, Page 481-500, March 2026.
The proposed mechanism by which Tui Na acupressure improves motor and cognitive dysfunction in ALS mice by activating the FoxP3/mTORC1 pathway. ABSTRACT Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease driven by neuroinflammation, where regulatory T cell (Treg) dysfunction exacerbates immune imbalance.
Jie Han, Xi Xu, Yan Zhao, Yao Xiao, Fei Huang, Jing Zhou, Hai Huang, Guiqian Wang   +7 more
wiley   +1 more source